Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Reactogenicity, and Immunogenicity of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine: a Single-blind and Randomized Study

NCT05132855 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.

NCT NCT05132855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05132855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Reactogenicity, and Immunogenicity of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine: a Single-blind and Randomized Study
Lead sponsor
Chang Gung Memorial Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 30, 2021
Completion date
April 30, 2023
Enrollment
340 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breakthrough infection, covid-19